Take a trial of UK to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Apr 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -13.7%

FINANCIAL BRIEF: For the six months ended 31 October 2013, Scancell Holdings Plc revenues was not reported. Net loss increased 29% to L1.2M. Higher net loss reflects Administration Expense increase of 50% to L640K (expense), Interest Income decrease of 78% to L4K (income). Basic Earnings per Share excluding Extraordinary Items totaled to -L0.01. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
E+
E+

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Oct '13) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Apr 2014
30th Apr 2015

Price Target: N/A Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (£) (£) (p) (£)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Scancell Holdings
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Cenkos Securities Navid Malik ,

Scancell Holdings PLC is a United Kingdom-based biopharmaceutical company. The Company’s principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. The Company’s cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase II clinical trials. SCIB1 is a plasmid Deoxyribonucleic Acid (DNA), which encodes a human antibody molecule engineered to express a melanoma antigen called Tyrosinase-Related Protein 2 (TRP2) plus two helper T cell epitopes.

Directors: Lindy Durrant (CEO) , Richard Goodfellow (CCE) , Sally Adams (OTH) 53, David Evans (NEC) 53, Katherine Cornish-Bowden (NED) 44, Matthew Frohn (NED) ,

No. of Employees: 7 No. of Shareholders: 0


Last Annual April 30th, 2013
Last Interim October 31st, 2013
Shares in Issue 224,950,683
Free Float 178.8m (79.5%)
ISIN GB00B63D3314
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Intl-aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

SCLP Share Price Performance SCLP Quote
35.25p
0.5  1.4%
Traded 2:45pm · Minimum 15 min delayed · NMS: 15.0k

Latest SCLP News Announcements (delayed)

Upcoming SCLP Events
Friday 31st October, 2014 (estimate)
Scancell Holdings PLC Annual Shareholders Meeting

Recent ↓
Tuesday 4th March, 2014
Scancell Holdings PLC at Sachs Associates EUROPEAN LIFE SCIENCE CEO FORUM PARTNERING & INVESTING IN BIOTECH & PHARMA INDUSTRY Conference
Monday 9th December, 2013
Interim 2013-2014 Scancell Holdings PLC Earnings Release
Friday 1st November, 2013
Scancell Holdings PLC Annual General Meeting
Tuesday 1st October, 2013
Scancell Holdings PLC Investor Day
Tuesday 9th July, 2013
Preliminary 2012-2013 Scancell Holdings PLC Earnings Release
Tuesday 26th July, 2011
Scancell Hldg PLC Split For SCLP.L


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy SCLP

Access SCLP Analytics Now!

FREE TRIAL or TAKE THE TOUR